Evotec Se - Adr Share Price Today
(NASDAQ: EVO)

Name: Evotec Se - Adr Share Price Today (NASDAQ: EVO) - Evotec Se - Adr Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Evotec Se - Adr share price is $4.22 & ₹368.96 as on 1 Mar 2025, 2.30 'hrs' IST

$4.22

▲

-0.17

(-3.87%)

Market is closed - opens 8 PM, 03 Mar 2025

View live Evotec Se - Adr share price in Dollar and Rupees. Guide to invest in Evotec Se - Adr stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Evotec Se - Adr, along with analyst recommendations, forecasts, and comprehensive financials.

Evotec Se - Adr share price movements

Today's Low: $4.22
Today's High: $4.34
$4.22
0.0%
Downside
Day's Volatility :2.76%
Upside
2.76%
52 Weeks Low: $2.85
52 Weeks High: $7.98
$4.22
32.46%
Downside
52 Weeks Volatility :64.29%
Upside
47.12%

Evotec Se - Adr (EVO) Returns

Period	Evotec Se - Adr	Sector (Health Care)	Index (Russel 2000)
3 Months	-10.59%	1.0%	0.0%
6 Months	22.32%	-5.3%	0.0%
1 Year	-43.96%	1.8%	0.0%
3 Years	-70.71%	15.2%	-11.9%

Evotec Se - Adr (EVO) Key Statistics

in dollars & INR

Previous Close	$4.39
Open	$4.33
Today's High	$4.34
Today's Low	$4.22
Market Capitalization	$1.5B
Today's Volume	$137.2K
52 Week High	$7.98
52 Week Low	$2.85
Revenue TTM	$777.1M
EBITDA	$15.9M
Earnings Per Share (EPS)	$-0.51
Profit Margin	-22.05%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-16.25%

How to invest in Evotec Se - Adr Stock (EVO) from India?

It is very easy for Indian residents to invest directly in Evotec Se - Adr from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Evotec Se - Adr stock in both Indian Rupees (INR) and US Dollars (USD). Search for Evotec Se - Adr or EVO on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Evotec Se - Adr or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Evotec Se - Adr shares which would translate to 0.207 fractional shares of Evotec Se - Adr as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Evotec Se - Adr, in just a few clicks!

Returns in Evotec Se - Adr (EVO) for Indian investors in Rupees

The Evotec Se - Adr stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Evotec Se - Adr investment value today

Current value as on today

₹61,553

Returns

₹38,447

(-38.45%)

Returns from Evotec Se - Adr Stock

₹43,958 (-43.96%)

Dollar Returns

₹5,510 (+5.51%)

Indian investors sentiment towards Evotec Se - Adr (EVO)

-18%

Period: Jan 29, 2025 to Feb 28, 2025. Change in 30 Days versus previous period

Search interest for Evotec Se - Adr Stock from India on INDmoney has decreased by -18% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Evotec Se - Adr

Mubadala Investment Company PJSC
1.29%
Wellington Management Company LLP
0.65%
BlackRock Inc
0.41%
DCF Advisers, LLC
0.06%
Morgan Stanley - Brokerage Accounts
0.04%
Goldman Sachs Group Inc
0.02%

Analyst Recommendation on Evotec Se - Adr

Buy

87%Buy

12%Hold

0%Sell

Based on 16 Wall street analysts offering stock ratings for Evotec Se - Adr(by analysts ranked 0 to 5 stars)

Based on 16 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Evotec Se - Adr Stock (EVO)

What analysts predicted

Upside of 48.99%

Target:

$6.29

Current:

$4.22

Insights on Evotec Se - Adr Stock (Ticker Symbol: EVO)

Price Movement
In the last 1 year, EVO stock has moved down by -44.0%
Increasing Revenue
Revenue is up for the last 2 quarters, 182.12M → 184.89M (in $), with an average increase of 1.5% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -94.93M → -39.63M (in $), with an average increase of 139.5% per quarter
EVO vs ITCI (1 yr)
In the last 1 year, Intra-cellular Therapies, Inc. has given 79.3% return, outperforming this stock by 123.3%
EVO vs ITCI (3 yr)
In the last 3 years, Intra-cellular Therapies, Inc. has given 126.9% return, outperforming this stock by 197.8%
Price to Sales
ForEVO every $1 of sales, investors are willing to pay $1.9, whereas for Intra-cellular Therapies, Inc., the investors are paying $19.4 for every $1 of sales.

EVO Evotec Se - Adr Financials in INR & Dollars

	FY19	Y/Y Change
Revenue	$496.1M	↑ 18.92%
Net Income	$42.4M	↓ 54.67%
Net Profit Margin	8.55%	↓ 13.87%

	FY20	Y/Y Change
Revenue	$609.3M	↑ 12.2%
Net Income	$7.6M	↓ 83.55%
Net Profit Margin	1.25%	↓ 7.3%

	FY21	Y/Y Change
Revenue	$698.7M	↑ 23.38%
Net Income	$243.6M	↑ 3332.78%
Net Profit Margin	34.87%	↑ 33.62%

	FY22	Y/Y Change
Revenue	$795.2M	↑ 21.59%
Net Income	$-185.9M	↓ 181.51%
Net Profit Margin	-23.38%	↓ 58.25%

	FY23	Y/Y Change
Revenue	$781.4M	↑ 3.99%
Net Income	$-83.9M	↓ 52.23%
Net Profit Margin	-10.74%	↑ 12.64%

	FY24	Y/Y Change
Revenue	$781.4M	↑ 0.0%
Net Income	$-83.9M	↑ 0.0%
Net Profit Margin	-10.74%	↑ 0.0%

	Q2 FY23	Q/Q Change
Revenue	$212.9M	↓ 18.45%
Net Income	$-42.3M	↑ 43.21%
Net Profit Margin	-19.85%	↓ 8.55%

	Q3 FY23	Q/Q Change
Revenue	$209.5M	↑ 0.0%
Net Income	$-41.6M	↑ 0.0%
Net Profit Margin	-19.85%	↑ 0.0%

	Q4 FY23	Q/Q Change
Revenue	$219.6M	↑ 2.57%
Net Income	$-17.6M	↓ 58.59%
Net Profit Margin	-8.01%	↑ 11.84%

	Q1 FY24	Q/Q Change
Revenue	$226.9M	↑ 3.68%
Net Income	$-22.5M	↑ 28.16%
Net Profit Margin	-9.9%	↓ 1.89%

	Q2 FY24	Q/Q Change
Revenue	$196.0M	↓ 12.75%
Net Income	$-102.2M	↑ 359.21%
Net Profit Margin	-52.13%	↓ 42.23%

	Q3 FY24	Q/Q Change
Revenue	$184.9M	↑ 1.52%
Net Income	$-39.6M	↓ 58.25%
Net Profit Margin	-21.44%	↑ 30.69%

	FY19	Y/Y Change
Profit	$147.7M	↑ 18.64%

	FY20	Y/Y Change
Profit	$152.9M	↓ 5.38%

	FY21	Y/Y Change
Profit	$171.3M	↑ 20.52%

	FY22	Y/Y Change
Profit	$184.2M	↑ 14.86%

	FY23	Y/Y Change
Profit	$175.1M	↑ 0.57%

	FY24	Y/Y Change
Profit	$175.1M	↑ 0.0%

	Q2 FY23	Q/Q Change
Profit	$41.0M	↓ 54.13%

	Q3 FY23	Q/Q Change
Profit	$40.4M	↑ 0.0%

	Q4 FY23	Q/Q Change
Profit	$41.1M	↓ 0.42%

	Q1 FY24	Q/Q Change
Profit	$37.8M	↓ 7.72%

	Q2 FY24	Q/Q Change
Profit	$16.9M	↓ 54.71%

	Q3 FY24	Q/Q Change
Profit	$18.3M	↑ 16.15%

	FY19	Y/Y Change
Operating Cash Flow	$46.9M	↓ 72.98%
Investing Cash Flow	$-96.3M	↑ 121.4%
Financing Cash Flow	$234.8M	↓ 371.67%

	FY20	Y/Y Change
Operating Cash Flow	$54.4M	↑ 5.93%
Investing Cash Flow	$-188.6M	↑ 79.02%
Financing Cash Flow	$299.7M	↑ 16.64%

	FY21	Y/Y Change
Operating Cash Flow	$138.2M	↑ 173.33%
Investing Cash Flow	$-275.7M	↑ 57.24%
Financing Cash Flow	$450.4M	↑ 61.69%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$22.5M	↓ 161.92%
Investing Cash Flow	$15.6M	↑ 0.0%
Financing Cash Flow	$47.0M	↓ 2312.65%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$22.2M	↑ 0.0%
Investing Cash Flow	$-16.8M	↓ 209.48%
Financing Cash Flow	$46.3M	↑ 0.0%

Evotec Se - Adr Technicals Summary

Sell

Neutral

Buy

Evotec Se - Adr is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Evotec Se - Adr (EVO) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Evotec Se - Adr	-6.01%	22.32%	-43.96%	-70.71%	-80.82%
Intra-cellular Therapies, Inc.	0.94%	75.62%	79.33%	124.72%	485.92%
Haleon Plc Spon Ads	6.37%	0.2%	20.47%	37.38%	37.38%
Zoetis Inc.	-3.17%	-8.9%	-12.36%	-14.7%	20.39%
Neurocrine Biosciences Inc.	-22.55%	-5.1%	-9.58%	29.24%	23.27%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Evotec Se - Adr	485.75	NA	NA	-0.9	-0.16	-0.02	NA	5.46
Intra-cellular Therapies, Inc.	NA	NA	0.0	0.18	-0.09	-0.07	NA	10.81
Haleon Plc Spon Ads	25.45	25.45	1.7	0.49	0.09	0.04	0.02	1.8
Zoetis Inc.	30.57	30.57	2.92	6.08	0.51	0.15	0.01	10.64
Neurocrine Biosciences Inc.	36.09	36.09	0.27	6.47	0.14	0.1	NA	26.05

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Evotec Se - Adr	Buy	$1.5B	-80.82%	485.75	-22.05%
Intra-cellular Therapies, Inc.	Buy	$13.6B	485.92%	NA	-10.97%
Haleon Plc Spon Ads	Buy	$47.1B	37.38%	25.45	12.84%
Zoetis Inc.	Buy	$74.9B	20.39%	30.57	26.86%
Neurocrine Biosciences Inc.	Buy	$11.8B	23.27%	36.09	14.49%

About Evotec Se - Adr

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Organization	Evotec Se - Adr
Employees	5007
CEO	Dr. Christian Wojczewski
Industry	Miscellaneous

Management People of Evotec Se - Adr

Name	Title
Ms. Laetitia Rouxel	CFO & Member of Management Board
Dr. Cord Dohrmann Ph.D.	Chief Scientific Officer & Member of Management Board
Dr. Christian Wojczewski	Chief Executive Officer
Ms. Aurelie Dalbiez	Chief People Officer & Member of Management Board
Mr. Volker Braun	Executive VP and Head of Global Investor Relations & ESG
Dr. Christian Dargel	EVP Global Head of Legal & Compliance
Gabriele Hansen	Senior VP & Head of Global Corporate Communications & Marketing
Dr. Ian M. Hunneyball	Senior Vice President of Programme Management & Clinical Operations
Dr. David Hallet	Executive Vice President
Uwe Andag	EVP Head of Metabolic Diseases

Important FAQs about investing in EVO Stock from India :

What is Evotec Se - Adr share price today?

Evotec Se - Adr share price today stands at $4.22, Open: $4.33 ; Previous Close: $4.39 ; High: $4.34 ; Low: $4.22 ; 52 Week High: $7.98 ; 52 Week Low: $2.85.

The stock opens at $4.33, after a previous close of $4.39. The stock reached a daily high of $4.34 and a low of $4.22, with a 52-week high of $7.98 and a 52-week low of $2.85.

Can Indians buy Evotec Se - Adr shares?

Yes, Indians can invest in the Evotec Se - Adr (EVO) from India.

With INDmoney, you can buy Evotec Se - Adr at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Evotec Se - Adr at zero transaction cost.

How can I buy Evotec Se - Adr shares from India?

It is very easy to buy Evotec Se - Adr from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Evotec Se - Adr (EVO) be purchased?

Yes, you can buy fractional shares of Evotec Se - Adr with INDmoney app.

What are the documents required to start investing in Evotec Se - Adr stocks?

To start investing in Evotec Se - Adr, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.